Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Game Time: FDA Releases Review Timeline Goals Set By MDUFA V

Executive Summary

This exclusive infographic shows new review timelines the FDA announced for FY 2023 now that MDUFA V has been ratified.

You may also be interested in...



FDA 2024: Watch For Trial-Diversity Guidance, Final Quality Systems Rewrite

Industry observers at RAPS Convergence in Montreal last week said the FDA’s agenda for 2024 is likely to include increased emphasis on MDUFA goals, enhanced cybersecurity requirements, the new QMSR, and more. 

Masimo’s MightySat Receives First FDA Clearance For OTC Pulse Oximeter

The first clearance from the US Food and Drug Administration for an over-the-counter fingertip pulse oximeter has gone to Masimo's MightySat Medical, which is now available at the company's website.

HHS Releases ‘Essential’ And ‘Enhanced’ Cybersecurity Performance Goals

HHS publishes a new website and releases its essential and enhanced voluntary cybersecurity performance goals.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT145907

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel